NULOJIX (belatacept) 250 mg powder for concentrate for solution for infusion and IMMUCYST 81 mg powder for intravesical suspension B.C.G. For Immunotherapy.
Being lack since few moths ago, Bristol-Myers Squibb (BMS) and Sanofi Pasteur announced to provide a soon as possible in particular Bristol-Myers Squibb (BMS) since Sanofi Pasteur provided in a while.
1- Indication of NULOJIX (belatacept) 250 mg powder for concentrate for solution for infusion:
NULOJIX, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for the prevention of graft rejection in adults receiving renal transplantation.
To this treatment including belatacept, it is recommended to add an interleukin 2 (IL-2) receptor antagonist for therapeutic induction.
2- Indication of IMMUCYST 81 mg powder for intravesical suspension B.C.G. For Immunotherapy:
Treatment of non-invasive urothelial carcinomas of the bladder:
Prophylactic and curative treatment of urothelial carcinoma in situ. Prophylactic treatment of relapses of urothelial carcinoma limited to the mucosa: Ta G1-G2 if multifocal and / or recurrent tumor, PTa G3, urothelial carcinoma invading the lamina propria but not the bladder muscle (pT1).
No comments:
Post a Comment